Sunday, June 26, 2022
Friday, June 24, 2022
NEWR/RXRX/BEAM
NEWR/RXRX/BEAM
- New Relic is a San Francisco, California-based technology company which develops cloud-based software to help website and application owners track the performances of their services. WikipediaCEO: Bill Staples (Jul 1, 2021–)Founder: Lew CirneFounded: 2008Headquarters: San Francisco, CANumber of employees: 2,217 (2022)Revenue: 667.7 million USD (March 2021)Subsidiaries: CodeStream, Inc., IOPipe, Inc., Opsmatic, Inc., Signifai Inc., New Relic K.K, Pixie Labs Inc.
- 52 Week Range41.66 - 129.70
- Volume
103,070 - Avg. Volume1,075,888
Market Cap 3.602B Beta (5Y Monthly) 1.01 - XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
- 52 Week Range4.92 - 42.81Volume
139,844 Avg. Volume1,020,396 Market Cap 1.555B Beta (5Y Monthly) N/A Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 450
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
- https://finance.yahoo.com/quote/beam
- 52 Week Range27.77 - 138
- .52Volume
282,631 - Avg. Volume1,328,369
Market Cap 3.04B Beta (5Y Monthly) 1.60 imilar to BEAM
Symbol Last Price Change % Change NTLA Intellia Therapeutics, Inc.
54.56 +3.80 +7.48% EDIT Editas Medicine, Inc.
13.61 +0.11 +0.81% CRBU Caribou Biosciences, Inc.
6.04 +0.15 +2.55% VERV Verve Therapeutics, Inc.
16.00 -0.18 -1.11% FATE Fate Therapeutics, Inc.
26.45 +0.84 +3.30%
Thursday, June 23, 2022
Samsara Inc. (IOT)
- Samsara Inc. is an American IoT company headquartered in San Francisco, California. The company has additional offices in San Jose, California, Atlanta, and London. Samsara develops a connected operations platform for tracking fleets of vehicles and other equipment. WikipediaFounder: Sanjit BiswasFounded: 2015Headquarters: San Francisco, CANumber of employees: 1,616 (2022)Revenue: 428 million USD (2021)
- https://www.fool.com/investing/stock-market/market-sectors/information-technology/iot-stocks/
- . One such fund is the Global X Internet of Things ETF (NASDAQ:SNSR), which holds positions in dozens of IoT-related companies, including Dexcom. Buying shares in an IoT-focused fund confers instant sector diversification.
- https://finance.yahoo.com/quote/iot/
52 Week Range 8.72 - 31.41 Volume 1,223,632 Avg. Volume 1,621,569
Market Cap 6.413B
- https://finance.yahoo.com/news/samsara-general-motors-optimize-cloud-180000860.html
52 Week Range | 8.72 - 31.41 |
Volume | |
Avg. Volume | 1,621,569 |
Market Cap | 6.413B |